Navigation Links
Metapneumovirus - a common cause of adults' colds, kids' illness

Researchers are beginning to piece together the scope of this ubiquitous but overlooked bug, which now appears to afflict just about everybody, probably over and over. Even though the virus seems to be rarely serious, its vast presence intrigues microbiologists.//

Like many other respiratory bugs, this one is most likely to cause severe illness in infants encountering it for the first time. Although repeat infections are thought to be common, they result in much less intense illness, often just an ordinary cold or perhaps no symptoms at all.

However, the bug may cause more serious problems in the elderly and people with other medical conditions. Although new microbes, such as the ones that cause AIDS and SARS, are occasionally recognized, it is unusual to discover a virus as omnipresent as this.

"Thousands of hospitalizations occur every year due to this virus in infants," say doctors.

Research suggests that the metapneumovirus is second only to respiratory syncytial virus as a cause of severe lower respiratory infections in the young, occurring about two-thirds as often. Both viruses are members of the paramyxovirus family.

Researchers looked at nasal specimens taken from 2,000 children after they were treated for lower respiratory infections since 1976.

The newly discovered virus turned out to cause about 12 percent of these severe illnesses. They also caused 15 percent of common colds in children, including one-third of the colds complicated by middle-ear infections. "When we put this in perspective, it appears to be the second most common cause of respiratory illnesses in children," they said.

Contracting over and over The virus went undiscovered because it does not grow well in cell cultures, a standard tool for sorting out the viruses that cause human disease. It was identified in 2001 by researchers from Erasmus Medical Center in Rotterdam.

They calculated that every child catches the
'"/>




Page: 1 2

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Iron supplementation for a common side effect
3. E. coli strains resistant to a common antibiotic
4. Gastrointestinal ills more common in diabetics
5. Toxic effects common with AIDS treatments
6. Drooping eyelids more common in men
7. Unnatural death common in mentally ill
8. New Drug, Pleconaril speeds recovery from common cold
9. Relief from common back pain
10. Drugs control and industry departments to share a common e-platform
11. Periodontitis a common problem in patients with arthritis

Post Your Comments:
(Date:12/3/2009).... 3 The Ensign Group, In...cquired SunView Care Center, an operating skilled ...na, a sister community adjacent to Arizona,s Sun C...ctive December 1, 2009. ,, (Logo : http://www...., "We are pleased to be adding a new facility a...
(Date:12/3/2009).... 3 A majority of Americans suppor...on, but most lack confidence that the cost, qualit...rove in the next year, according to a survey relea...of survey respondents said they believe a public o...m legislation. Only about one in five, however, be...
(Date:12/2/2009)...ec. 3 Van Andel Research Institute...the plant hormone abscisic acid (ABA) works at the...mental stresses such as drought and cold. Their f...help engineer crops that thrive in harsh environme...ges. The findings could also have implications fo...
(Date:12/2/2009)... Reportlinker.com announces that a ...alogue: ,, Sterilization Technologies: The U....66820/Sterilization-Technologies-The-US-Market.htm...al equipment to the sterilization industry in 2008...h rate for 2009-2014. ,, Explains how the trend...
(Date:12/2/2009)... Reportlinker.com announces that a...talogue: ,, Kinase Inhibitors: Global Markets...nase-Inhibitors-Global-Markets.html ,, Forec... years 2005 through 2008, and projections for the ...rough 2014 ,, An overview of the market for th...
Breaking Medicine News(10 mins):Health News:The Ensign Group Acquires Arizona Skilled Nursing Facility 2Health News:Thomson Reuters Survey: Most Americans Support Public Option in Healthcare Reform Legislation but Are Skeptical Healthcare Will Improve in 2010 2Health News:VAI Researchers Find Long Awaited Key to Creating Drought Resistant Crops 2Health News:VAI Researchers Find Long Awaited Key to Creating Drought Resistant Crops 3Health News:VAI Researchers Find Long Awaited Key to Creating Drought Resistant Crops 4Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 2Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 3Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 4Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 5Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 6Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 7Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 8Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 9Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 10Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 11Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 12Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 13Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 2Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 3Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 4Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 5Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 6Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 7Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 8Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 9Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 10Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 11Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 12Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 13Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 14Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 15
...PERVILLE, Ill., Dec. 4 NAMC members can gain acce... desktop. Webinars feature nationally-recognized s...uter. The next webinar will be on December 10, 20... do you know how to engage them? , This webinar...
...rld-Class Health Care Brought Closer to More Veter...e easier access to world-class health care under a...31 new outpatient clinics in 16 states. , , ...waii, Illinois, Iowa, Maryland, Michigan, Minnesot...
...0 minutes of moderate-intensity activity or 75 min...DAY, Dec. 4 (HealthDay News) -- An estimated 65 pe... the 2008 Physical Activity Guidelines for America...ding to the 2008 guidelines, released in October b...
...SHINGTON, Dec. 4 On this International Day for t... American Health and Education Foundation (PAHEF) ...ention project. The project has advanced awareness...stment that Saves Lives , Edward Kadunc, PAHEF Exe...
...DIANAPOLIS, Dec. 4 The Commander of The American ...owing statement concerning illegal drug traffickin... , "The men and women of The American Legion D...h VA Medical Center with dismay and keen interest....
... DALLAS Dec. 4, 2008 Use of the drug interferon ...ogression of liver disease associated with the hep...ical Center researchers and their colleagues from ...t Against Cirrhosis) Trial, appear in today,s issu...
Other Medicine News:Health News:New NAMC Member Service! Complimentary Webinars for NAMC Members - On Topics You Need to Know! Sign Up Today for This New and Exciting Educational Program! 2Health News:VA Opening 31 New Outpatient Clinics 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 3Health News:PAHEF Works to Prevent Violence Against Women 2Health News:American Legion, Department of Indiana Releases Statement Concerning Revelations of Illicit Drug Trafficking at Roudebush VA Medical Center 2Health News:HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective 2
(Date:12/2/2009)...RK, Dec. 2 Reportlinker.com announ... in its catalogue: ,, Immunoassay Instruments ...nker.com/p0164367/Immunoassay-Instruments---Global...logy markets have recorded significant growth in r...ies and introduction of new products. New tests ar...
(Date:12/2/2009)...K, Dec. 2 Reportlinker.com announc...in its catalogue: ,, EEG/EMG/Brain Function M...ww.reportlinker.com/p0164319/EEG/EMG/Brain-Functio...eep rise in obesity, cardiovascular, and autoimmun...raph (EEG) diagnostic and monitoring equipment glo...
(Date:12/2/2009)...Pa., Dec. 2 Cephalon, In...led a lawsuit in U.S. District Court in Delaware a...ment of U.S. Patent Nos. 7,132,570 (the ",570 Pate...the ",516 Patent") for the Cephalon product NUVIGI...s a three-year period of marketing exclusivity for...
Breaking Medicine Technology:Reportlinker Adds Immunoassay Instruments - Global Market Trends 2Reportlinker Adds Immunoassay Instruments - Global Market Trends 3Reportlinker Adds Immunoassay Instruments - Global Market Trends 4Reportlinker Adds Immunoassay Instruments - Global Market Trends 5Reportlinker Adds Immunoassay Instruments - Global Market Trends 6Reportlinker Adds Immunoassay Instruments - Global Market Trends 7Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 2Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 3Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 4Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 5Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 6Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 7Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 8Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 1Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 2Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 59578 1Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 59578 2Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 59578 3Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 59578 4Want Sun Protection 3F Wear Red or Blue 59575 1
...SINESS WIRE)--Jun 25, 2007 - Neurogen,Corporation ...esults from two dose-ranging, Phase 2b clinical tr...,s proprietary insomnia agent,NG2-73, an alpha-3 ...lations were studied in each trial to determine th...ntenance of sleep,through the night without residu...
...SS WIRE)--Jun 25, 2007 - CytRx Corporation,(NASDAQ...,development and commercialization of human therap...ults from its previously,announced double-blind, p...rial in healthy volunteers with its drug candidate...his trial support,the use of arimoclomol in future...
Other Medicine Technology:Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 2Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 3Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 4Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 5Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 6Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 7Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 8CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 2CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 3CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 4CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 5
Lacrimal Cannula, 19 g / 23 g. Curved
Anterior Chamber Needle, 27 g. Angled
Anterior Chamber Needle, 20 g. Angled
Retinal Hydrodissection Cannula 41 Gauge I.D.
Medicine Products: